Full Press Release Details
Lexaria Files International Cannabinoid Patent
Kelowna, BC December 19, 2016 - Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the Company or Lexaria ) is pleased to announce,
following the successful October 26, 2016 issuance of its U.S. Patent No.
9,474,725, Cannabinoid Infused Food and Beverage Compositions and Methods of Use
Thereof, it has filed to expand this patent internationally. National filing
patent applications in Canada, Australia, Japan, China, India and all 37
countries belonging to the European Patent Convention have just been filed. All
of these filings follow the initial international Patent Cooperation Treaty
( PCT ) Patent Appl. No PCT/US2015/035128. Lexaria has also filed two new
international patent applications under the PCT. These two applications are
entitled Methods For Formulating Orally Ingestible Compositions Comprising
Lipophilic Active Agents, and Stable Ready-To-Drink Beverage Compositions
Comprising Lipophilic Active Agents. These two patent applications were original
filed in the United States on December 9, 2015, and are now being filed
Lexaria s patented technology has been lab tested to
demonstrate important benefits to consumers including shortened time of onset
and improved bioavailability for cannabinoid edibles. Taste is also improved for
many bioactive compounds including cannabinoids, in food, beverage, and other
Lexaria s patent applications are advancing as the Company
continues to expand its patent portfolio with the strategy of owning the
broadest and most important bioscience intellectual property portfolio relating
to cannabinoids and other molecules.
The Company has several other patent-pending applications in
the U.S. and internationally and believes it is well positioned for allowance of
these additional patent claim sets. These patent-pending applications expand the
breadth and variety of dosage formats and carrier molecules the Company s
technology can empower.
Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company s lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
masking taste. This technology promotes healthy ingestion methods, lower overall
dosing and higher effectiveness in active molecule delivery. The Company s
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes
forward-looking statements. Statements which are not historical facts are
forward-looking statements. The Company makes forward-looking public statements
concerning its expected future financial position, results of operations, cash
flows, financing plans, business strategy, products and services, competitive
positions, growth opportunities, plans and objectives of management for future
operations, including statements that include words such as "anticipate," "if,"
"believe," "plan," "estimate," "expect," "intend," "may," "could," "should,"
"will," and other similar expressions are forward-looking statements, including
but not limited to: that the Company s technology enables higher rates of
absorption of certain molecules such as vitamins and cannabinoids while
simultaneously masking and at times even eliminating inherent strong flavors
and/or odors typical of those molecules, or that the technology will function in
a similar manner if tested with THC, nicotine, or any of the other molecules
named in our patent applications. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Access to capital, or lack thereof, is a major risk and there is no assurance
that the Company will be able to raise required working capital. Factors which
could cause actual results to differ materially from those estimated by the
Company include, but are not limited to, government regulation, managing and
maintaining growth, the effect of adverse publicity, litigation, competition,
the patent applications and approval process and other factors which may be
identified from time to time in the Company's public announcements and filings.
There is no assurance that any license agreement, hemp oil sector, or
alternative health businesses will provide any benefit to Lexaria, or that the
Company will experience any growth through participation in these sectors or as
a result of the granted patent. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance that Lexaria s technology will deliver any
improvement in taste or bioavailability with any reliability nor across any
product category. There is no assurance that any planned corporate activity,
business venture, or initiative will be pursued, or if pursued, will be
successful. There is no assurance that any hemp oil or cannabinoid-based product
will promote, assist, or maintain any beneficial human health conditions
whatsoever, nor that any patent application in the USA or any other nation or
under any treaty will result in the award of an actual patent; nor that an award
of any actual patent will protect against challenges from unknown third parties.
There is no assurance that any of Lexaria s postulated uses, benefits, or
advantages for the patented and patent-pending technology will in fact be
realized in any manner or in any part. No statement herein has been evaluated by
the Food and Drug Administration (FDA). Lexaria Energy Foods and
ViPovaTM products are not intended to diagnose, treat, cure or
prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.